Recombinant FSH is produced through recombinant DNA technology. These products are pure and do not contain the "contaminants" seen in urine extraction FSH. It is given subcutaneously with much less discomfort. Both human and genetically derived products are difficult to obtain and manufacture and are therefore expensive.

Market Analysis and Insights: Global Recombinant Follicle Stimulating Hormone Market
In 2020, the global Recombinant Follicle Stimulating Hormone market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% between 2021 and 2027
Global Recombinant Follicle Stimulating Hormone Scope and Market Size
The global Recombinant Follicle Stimulating Hormone market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Follicle Stimulating Hormone market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), byType, and by Application for the period 2016-2027.

Segment by Type
75IU
150IU
Others

Segment by Application
Infertility Treatment
Assisted Reproductive Technology

By Company
Merck Serono
MSD
Techwell
GenSci
Gedeon Richter
Teva

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Colombia
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE